Inspira Technologies OXY B.H.N. Ltd. announced the signing of a collaboration term sheet (the ?Term Sheet?) with the Beilinson Hospital in Israel for the evaluation of its proprietary INSPIRA ART100 device (the ?Device?) in organ transplant procedures. This Term Sheet marks a significant advancement and opportunity for the Company in its technology being extended for use in additional medical segments and markets. Under the evaluation agreement contemplated by the Term Sheet, the hospital shall provide Inspira with access to the internally logged data and diagnostics from the use of the Device and user feedback from medical doctors, certified clinical perfusionists, and other caregivers.

The data is intended to be freely used by Inspira. Beilinson Hospital is the leading organ transplant center in Israel, conducting over 70% of the organ transplants in Israel. To date, it has performed thousands of procedures, including more than 900 lung transplants.

As a pioneering institution in kidney, lung, heart, liver, and pancreas transplants, the Beilinson Hospital oversees multiple organ donor programs and is involved in international research studies. The Term Sheet addresses the use of Inspira?s proprietary INSPIRA ART100 device in medical procedures in intensive care units for life support and operating rooms to support organ transplants. The primary objectives of the evaluation agreement are to assess the functionality and performance of the Device in clinical settings and healthcare delivery.

The collaboration agreement is conditional on regulatory clearance for the Device from the Israeli Ministry of Health Medical Device Division.